NEW YORK (GenomeWeb) – Twist Bioscience has priced a public offering of 3.75 million shares of its common stock at $21 per share. Twist anticipates gross proceeds of $78.8 million from the offering.
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?Login Now.
Don't have a GenomeWeb or 360Dx account?Register for Free.
In PLOS this week: transcriptomic and genomic analysis of prostate cancer by ancestry, genes linked to liver function in Korean cohort, and more.
British Columbia is incorporating genomics into its tracking of the ongoing COVID-19 outbreak, Business in Vancouver reports.
An analysis by the Personalized Medicine Coalition finds that about a quarter of new drugs approved in 2019 by the US Food and Drug Administration were personalized medicines.
The governor of New York has proposed a five-year plan to study the genomes of people with or who are at high risk of developing Alzheimer's disease.
This webinar will discuss a study that used long-read transcriptome sequencing to explore the distribution of isoforms in colon cancer samples and their metastasis counterparts.
This webinar will explain how the Clinic for Special Children in Strasburg, Pennsylvania, has transformed its DNA workflows to improve the diagnosis and treatment of genetic illnesses that are prevalent in the pediatric population of its community.
This webinar will discuss data from a recent real-world comparison study evaluating performance of two cell-free DNA methodologies as first-line prenatal screens.
This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.